PetVivo (US:PETV)2025-06-25 09:17Company Highlights - PetVivo focuses on the estimated $11 billion companion animal veterinary care and product sales market[8, 103] - Spryng, with OsteoCushion Technology, is designed to restore joint mechanics for managing lameness and joint-related issues like osteoarthritis[8, 103] - The company has a strong IP portfolio with twelve U S and nine foreign issued patents[8, 22, 84, 103] Spryng Technology and Clinical Data - Spryng utilizes biocompatible materials similar to natural cartilage components to improve joint function[18] - Clinical studies show that 77.8% of dogs experienced a greater than 3-point reduction in total CBPI score after Spryng treatment for hip osteoarthritis[64] - Another canine stifle OA/CCL disease study showed that 55% of dogs had improved mGCPS at 28 days, and by 84 days, responders improved in VLS and LOAD scores by 50%[67] - Tolerance studies in both dogs and cats confirmed the excellent safety profile of Spryng, with no abnormalities observed in physical exams, CBC, or chemistry analysis after injections[58, 61] Market and Distribution - The U S pet spend increased from $123.6 billion in 2021 to $138 billion in 2022, with veterinary care and products being a leading growth driver at $11 billion in 2021[91] - PetVivo has distribution agreements with MWI and Covetrus, and engagements with wholesale partners like Clipper Distributing Company and Vedco, Inc[8, 49, 103]